Abstracts present study was to determine whether a chronic treatment with a NO synthase inhibitor, L-NAME (Nω-nitro-L-arginine methyl ester) accelerates the renal dysfunction in younger adult spontaneously hypertensive rats (SHR). Indeed, in this model, the alterations in cardiac function mimic those observed in aging SHR. Male SHR were subjected to chronic L-NAME-treatment (6 mg/ kg/day) for two weeks. At 19 weeks, the kidneys were isolated, perfused with oxygenated physiological salt solution and changes in renal perfusion pressure continuously recorded. During a sustained constriction caused by methoxamine, bolus injections of acetylcholine and of the NO donor sodium nitroprusside caused dose-dependent dilatations in both groups of SHR. The responses to acetylcholine were not affected by the L-NAME treatment while those to sodium nitroprusside were signiÀ cantly augmented. In the two groups, indomethacin, a cyclooxygenase inhibitor, did not affect the vasodilatation caused by acetylcholine. However, an acute treatment with another NO synthase inhibitor, L-nitroarginine, produced a major inhibition of the acetylcholine response in the SHR while it did not affect it in the kidney of SHR chronically treated with L-NAME. In the presence of indomethacin plus L-nitro-arginine, TRAM-34, an inhibitor of Ca2+-activated K+ channels of intermediate conductance, IK(Ca), blocked the responses to acetylcholine in both groups of SHR. These data show that in SHR, the acetylcholine-induced vasodilatation involves both NO release and an endothelium-derived hyperpolarizing factor (EDHF)-mediated component while in the L-NAME-treated SHR, the NO-component is abolished and the EDHF-mediated component becomes the major contributor to this vasodilatation. In the kidney of L-NAME-treated SHR, EDHF-mediated responses are a compensatory mechanism that sustain endothelium-dependent dilatations when NO activity is impaired. The responses involve IK(Ca), activation and must be further characterized.
present study was to determine whether a chronic treatment with a NO synthase inhibitor, L-NAME (Nω-nitro-L-arginine methyl ester) accelerates the renal dysfunction in younger adult spontaneously hypertensive rats (SHR) . Indeed, in this model, the alterations in cardiac function mimic those observed in aging SHR. Male SHR were subjected to chronic L-NAME-treatment (6 mg/ kg/day) for two weeks. At 19 weeks, the kidneys were isolated, perfused with oxygenated physiological salt solution and changes in renal perfusion pressure continuously recorded. During a sustained constriction caused by methoxamine, bolus injections of acetylcholine and of the NO donor sodium nitroprusside caused dose-dependent dilatations in both groups of SHR. The responses to acetylcholine were not affected by the L-NAME treatment while those to sodium nitroprusside were signiÀ cantly augmented. In the two groups, indomethacin, a cyclooxygenase inhibitor, did not affect the vasodilatation caused by acetylcholine. However, an acute treatment with another NO synthase inhibitor, L-nitroarginine, produced a major inhibition of the acetylcholine response in the SHR while it did not affect it in the kidney of SHR chronically treated with L-NAME. In the presence of indomethacin plus L-nitro-arginine, TRAM-34, an inhibitor of Ca2+-activated K+ channels of intermediate conductance, IK(Ca), blocked the responses to acetylcholine in both groups of SHR. These data show that in SHR, the acetylcholine-induced vasodilatation involves both NO release and an endothelium-derived hyperpolarizing factor (EDHF)-mediated component while in the L-NAME-treated SHR, the NO-component is abolished and the EDHF-mediated component becomes the major contributor to this vasodilatation. In the kidney of L-NAME-treated SHR, EDHF-mediated responses are a compensatory mechanism that sustain endothelium-dependent dilatations when NO activity is impaired. The responses involve IK(Ca), activation and must be further characterized. Our aim was to better understand the changes in expression in vascular smooth muscle cells during ageing using non pathological human mammary artery. We deÀ ned 2 groups of patients: a group of young ones, Y, composed of men under 60 years old (43 to 60, 13 patients) and a group of old ones, O, composed of men over 75 years old (75 to 83, 11 patients). After dissection of the artery, medias were crushed and total RNA including microRNAs were collected.
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IDENTIFICATION OF NEW BIOMARKERS OF VASCULAR SMOOTH MUSCLE CELLS AGEING FROM TRANSCRIPTOMIC AND MIRNA STUDIES
Using microRNA array, we found that 90 microRNAs are expressed in the media from these patients. After statistical analysis no change in microRNA expression was found between the O and the Y groups. Therewere a lot of heterogeneity between the patients inside each group. It seems that vascular aging do not affect miRNA expression in our study, but the two groups of age were maybe too close to see some regulation.
Using DNA microarray, we found 233 genes signiÀ catively regulated between the O group and the Y group. Among them, 60 genes were modulated more than 1.4 fold. We choose to verify these expression changes for 20 of them (the most regulated, newly identiÀ ed or implicated in ageing) by quantitative RT-PCR and conÀ rmed the regulation for 14 genes: compared to the Y, in the O group we saw an overexpression (from 1.4 to 8 fold) for 9 genes and an inhibition (from -1.5 to -3.2 fold) for 5 other genes. We focused on overexpressed Osteopontin, WISP1 (Wnt inducible secreted protein 1), Gamma S Crystallin (for instance only described in lens and which could be a chaperon) and on inhibited Cystathionase (which produces H2S, an artery vasodilatator). The changes observed in mRNA expression were also seen in protein expression by Western Blot although less clearly due to strong inter-individual variability.
We also found that Wnt/beta-catenin signalization pathway was more activated in the O group. We notably found that beta-catenin phosphorylation on Ser 552 and Ser 675, which leads to betacatenin transfer in the nucleus, was increased.
C016
CONTRIBUTION DU STRESS OXYDANT GENERE PAR LA MAO-A AU COURS DE LA DEGRADATION DE LA SEROTONINE DANS LE REMODELAGE CARDIAQUE ASSOCIE AU VIEILLISSEMENT
Le remodelage cardiaque au cours du vieillissement est caractérisé par une réduction massive du nombre de cardiomyocytes qui participe aux dysfonctionnements cardiaques observés chez le sujet âgé. Cette perte de cardiomyocytes par nécrose ou apoptose s'accompagne d'une part de l'hypertrophie compensatrice des cardiomyocytes restants, et d'autre part du dépôt de matrice extracellulaire conduisant à la À brose et la rigidiÀ cation du myocarde. Le stress oxydant est un élément déterminant du remodelage cardiaque chez les individus âgés. Nous avons montré que la Monoamine oxydase-A (MAO-A) est une source de stress oxydant dans le coeur et que son expression est fortement augmentée dans le coeur âgé. De plus, la production d'H202 par la MAO-A lors la dégradation de sérotonine, induit l'apoptose et la nécrose des cardiomyocytes in vitro. De ce fait, l'augmentation de l'activité de la MAO-A au cours du vieillissement pourrait conduire au remodelage et à l'insufÀ sance cardiaque via l'accumulation d'H202.
AÀ n de modéliser l'augmentation de l'expression de la MAO-A au cours du vieillissement, nous avons établi des lignées de souris transgéniques surexprimant la MAO-A sous le contrôle du promoteur α-MHC. Deux lignées dénommées 61 et 113 ont été obtenues, qui présentent une surexpression cardiaque spéciÀ que de la MAO-A de 9142 et 38526 pmol/min/mg de protéines respectivement par rapport aux souris non transgéniques (31 pmol/min/mg prot) ainsi qu'un taux basal de H202 mitochondrial accru. De manière intéressante, ces deux lignées présentent une mortalité précoce, corrélée avec l'activité de la MAO-A dans le coeur. La caractérisation fonctionnelle par échocardiographie montre une baisse importante des performances cardiaques et une dilatation du ventricule gauche, caractéristiques des stades tardifs de l'insufÀ sance cardiaque. L'analyse histologique réalisée sur ces lignées montre une réduction précoce et massive du nombre de cardiomyocytes par nécrose en comparaison aux souris non transgéniques. Cette perte de cardiomyocytes s'accompagne progressivement d'une hypertrophie compensatrice des cardiomyocytes restants et de lésions À brotiques, rappelant le phénotype d'un coeur âgé. En conclusion, ces données montrent qu'une augmentation de la MAO-A au cours du vieillissement pourrait favoriser la perte des cardiomyocytes par nécrose et ainsi précipiter le remodelage ventriculaire. L'étude menée sur des artères iliaques de lapin montées sur myographe montre que l'AA (1 mmol/L) et BH4 (200 õmol/L) augmentent la relaxation de type EDHF induite par l'acide cyclopiazonique (CPA) inhibiteur SERCA et l'acétylcholine (ACh) un agoniste de la protéine G. Cet effet potentialisateur est abolit en présence de catalase sous-tendant un rôle du peroxyde d'hydrogène (H2O2). En effet, la méthode de dosage amplex-red/ HRP conÀ rme la génération d'H2O2 par l'oxydation de l'AA et de BH4. D'autre part, l'ajout dans le bain d'incubation d'H2O2 exogène à dose similaire de l'H2O2 produit par l'oxydation de l'AA et BH4 mime l'action potentialisatrice de ces deux substances. Contrairement à l'AA, en présence de superoxyde dismutase, la formation d'H2O2 par BH4 est diminuée. Le DTPA, un chélateur de métaux permet de diminuer la production d'H2O2 par l'AA. Ceci indique que la génération d'H2O2 est liée principalement à la présence de l'anion superoxyde pour BH4 tandis que pour l'AA elle dépend plus des traces de métaux. Le blocage des gap jonctions par l'utilisation de peptides mimétiques des connexines inhibe à la fois les relaxations témoins et potentialisées conÀ rmant la nature éléctrotonique du phénomène EDHF dans chacun des cas.
C017 L'ACIDE ASCORBIQUE ET LA TETRAHYDROBIOPTERINE POTENTIALISENT LE PHÉNOMÈNE EDHF PAR GÉNÉRATION DE PEROXYDE D'HYDROGÈNE
De nombreuses études ont rapporté l'effet bénéÀ que des propriétés anti-oxydantes de l'AA et de BH4 sur la relaxation NOdépendante. Nos résultats montrent que les effets pro-oxydant de ces substances peuvent eux aussi améliorer les dysfonctions vasculaires en générant de l'H2O2 par l'oxydation de l'AA catalysé par des métaux et l'autoxydation de BH4. En effet, lorsque la synthèse de NO est inhibée de façon pharmacologique, l'oxydation de ces agents conduit à la formation d'H2O2 ampliÀ ant la relaxation artérielle de type EDHF. La production d'H2O2 à partir du peroxyde est habituellement atténuée par le NO donnant le peroxynitrite, en compétition avec la superoxyde dismutase. Il est donc possible qu'en cas de stress oxydatif important, caractérisant de nombreuses pathologies vasculaires, le phénomène EDHF soit potentialisé pour contrebalancer la réduction de biodisponibilité du NO.
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MYCOPHENOLATE MOFETIL PREVENTS CYCLOSPORINE INDUCED ENDOTHELIAL DYSFUNCTION IN RAT ALLOGRAFT AORTIC MODEL
C. FREGUIN 1 , R. JOANNIDES 1,3 , N. ROUX 1,4 , V. RICHARD 1 , D. PLISSONNIER 1,4 , C. THUILLEZ 1,3 , M. GODIN 2 1 Inserm U644, Rouen, France 2 Nephrology, Rouen University Hospital, Bois Guillaume, France 3 Pharmacology, Rouen University Hospital, Rouen, France 4 Vascular surgery, Rouen University Hospital, Rouen, France Systemic endothelial dysfunction and increased arterial sensitivity to vasoconstrictor agents are commonly observed after renal transplantation and appear partly related to the vascular toxicity of calcineurin inhibitors, that promote oxidative stress and decrease nitric oxide (NO) availability. We tested whether the inhibitor of inosine monophosphate deshydrogenase mycophenolate mofetil (MMF), an immunosuppressive agent with antioxidant properties, prevents the deleterious endothelial effects of cyclosporine A (CsA) in a rat allograft aortic model. Four groups of Lewis rats (n=7 per group), grafted with an aortic abdominal allograft from a Brown Norway donor, were fed for two weeks with either vehicle (control), CsA (5 mg/ kg/day), MMF (40 mg/kg/day), or CsA+MMF. Arterial pressure was measured by tail cuff plethysmography. At day 15 after transplantation, endothelium-dependent (acetylcholine: Ach) and independent relaxations (sodium nitroprusside: SNP) were assessed in native thoracic aortic segments. Thoracic aortas were incubated with the NO-synthase inhibitor LNNA (10-5 mol/L) to assess the contribution of NO in acetylcholine-induced relaxation. Moreover, the concentration of phenylephrine (Phe) providing the half-maximum vasoconstriction (EC50) was determined and 8-isoprostane plasma levels were measured (ELISA, n=3-5 per group). CsA impaired the relaxation to Ach compared with control and MMF alone. Combined treatment with MMF+CsA restored these relaxing responses (Figure 1) . The relaxations to Ach were abolished by LNNA in all groups. There was no difference between groups for arterial pressure and the relaxation to SNP. Both MMF treated and control groups displayed similar dose response curves to Phe (Figure 2 Figure 1 
